Drug peptide conjugates in human urine?

References

• Archer S. (1985). The chemistry of schistosomiasis. Ann Rev Pharmacol Toxicol 25:485–508
   PubMed Web of Science ®Google Scholar
• Archer S, el-Hamouly W, Seyed-Mozaffari A, et al. (1990). Mode of action of the schistosomicide hycanthone: site of DNA alkylation. Mol Biochem Parasitol 43:89–95
   PubMedGoogle Scholar
• Archer S, Suter CM. (1952). The preparation of some 1-alkylamino- and dialkylaminoalkylaminothiaxanthones. J Amer Chem Soc 74:4296–309
   Google Scholar
• Archer S, Yarinsky A. (1972). Recent developments in the chemotherapy of schistosomiasis. In: Jucker E, ed. Progress in drug research. Basel/Stuttgart: Birkhauser, 11–67
   Google Scholar
• Baugh CM, Krumdieck CL, Nair MG. (1973). Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 52:27–34
   PubMed Web of Science ®Google Scholar
• Berberian DA, Freele H, Rosi D, et al. (1967). Schistosomicidal activity of lucanthone hydrochloride and their metabolites in mice and hamsters. J Parasitol 53:306–11
   PubMedGoogle Scholar
• Blair DM. (1958). Lucanthone hydrochloride, a review. Bull World Health Org 18:989–1010
   PubMedGoogle Scholar
• Bond HW. (1969). Chemistry of schistosomicides. Ann N Y Acad Sci 160:519–29
   PubMedGoogle Scholar
• Carew JS, Espitia CM, Esquivel JA, et al. (2011). Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem 286:6602–13
   PubMed Web of Science ®Google Scholar
• Christopherson JB. (1918). The successful use of antimony in bilharziosis. Lancet 192:325
   Google Scholar
• Cioli D, Pica-Mattoccia L, Rosenberg S, Archer S. (1985). Evidence for the mode of antischistosomal action of hycanthone. Life Sci 37:161–7
   PubMedGoogle Scholar
• Clare NT. (1947). A photosensitized keratitis in young cattle following the use of phenothiazine as an anthelmintic. Aust Vet J 23:340–4
   Google Scholar
• Clare NT. (1962). Metabolic products of phenothiazine in farm animals. Psychopharm Serv Cent Bull 2:44
   PubMedGoogle Scholar
• Colaco ATF. (1949). Miracil D in the treatment of vesical schistosomiasis. Anais Inst Med Trop 6:149–63
   PubMedGoogle Scholar
• Coxon RV, Latner AL, King E J. (1947). The estimation of miracil in urine. Biochem J 41:320–1, Proceedings, 30
   Google Scholar
• Dassonneville L, Bailly C. (1999). Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone. Biochem Pharmacol 58:1307–12
   PubMed Web of Science ®Google Scholar
• Del Rowe JD, Bello J, Mitnick R, et al. (1999). Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radiat Oncol Biol Phys 43:89–93
   PubMed Web of Science ®Google Scholar
• Gönnert R. (1961). The structure-activity relationship in several schistosomicidal compounds. Bull World Health Org 25:702–6
   PubMedGoogle Scholar
• Gönnert R, Kölling H. (1962). Thioxanthones and related compounds in experimental schistosomiasis. In: Goodwin LG, Nimmo-Smith RH, eds. Drugs, parasites and hosts. London: J & A Churchill Ltd., 29–42
   Google Scholar
• Good DM, Zurbig P, Argilés A, et al. (2010). Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9:2424–37
   PubMed Web of Science ®Google Scholar
• Hackmann C, Gönnert R, Mauss H. (1949). Untersuchungen über die tumorhemmende Wirkung des Miracils. Naturwissenschaften 36:29
   Google Scholar
• Halawani A, Newsome J, Wooton IDP. (1947). Miracil D; Investigations of blood levels after a single dose. J Egypt Med Assoc 30:656–62
   PubMedGoogle Scholar
• Harder A. (2002). Milestones of helmintic research at Bayer. Parasitology Res 88:477–80
   PubMedGoogle Scholar
• Hartman PE, Hulbert PB, Bueding E, Taylor DD. (1975). Microsomal activation of mutagens of antischistosomal methyl thioxanthenones and initial tests on a possibly non-mutagenic analogue. Mutat Res 31:87–95
   PubMed Web of Science ®Google Scholar
• Hawking F, Ross WF. (1948). Miracil D, its toxicology, absorption, and excretion in animals and humans. Br J Pharmacol 3:167–73
   Web of Science ®Google Scholar
• Hecht G. (1945). C.I.O.S. Report, File XXV-54, p. 124
   Google Scholar
• Hillman GR, Senft AW. (1975). Anticholinergic properties of the antischistosomal drug hycanthone. Amer J Trop Med Hyg 24:827–34
   PubMedGoogle Scholar
• Hirschberg E. (1975). Thiaxanthenones: Miracil D and hycanthone. Antibiotics 3:274–302
   Google Scholar
• Hirschberg E, Weinstein B, Gersten N, et al. (1968). Structure-activity studies on the mechanism of action of miracil D. Cancer Res 28:601–7
   PubMed Web of Science ®Google Scholar
• Huckle KR, Climie IJG, Hutson DH, Millburn P. (1981). Dipeptide conjugation of 3-phenoxybenzoic acid in the mallard duck. Drug Metab Dispos 9:147–9
   PubMed Web of Science ®Google Scholar
• Israili ZH, Dayton PG, Kiechiel JR. (1977). Novel routes of drug metabolism: a survey. Drug Metab Dispos 5:411–15
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Derr CJ, Johns DG. (1977). Accumulation of methotrexate diglutamate in human liver during methotrexate therapy. Biochem Pharmacol 26:2310–13
   PubMed Web of Science ®Google Scholar
• Kaihara M, Price JM. (1961). Quinaldylglycyltaurine: a urinary metabolite of quinaldic acid and kynurenic acid in the cat. J Biol Chem 236:508–11
   PubMed Web of Science ®Google Scholar
• Kaihara M, Price JM. (1965). The metabolism of quinaldylglyclglycine, a urinary metabolite of quinaldic caid in the cat. J Biol Chem 240:454–6
   PubMed Web of Science ®Google Scholar
• Kikuth W, Gönnert R. (1945). C.I.O.S. Report, File XXV-54, p.122
   Google Scholar
• Kikuth W, Gönnert R. (1948). Experimental studies on the therapy of schistosomiasis. Ann Trop Med Parasitol 42:256–67
   PubMed Web of Science ®Google Scholar
• Kikuth W, Gönnert R, Mauss H. (1946). Miracil, ein neues Chemotherapeuticum gegen die Darmbilharziose. Naturwissenschaften 33:253
   Web of Science ®Google Scholar
• Kohlhepp SJ, May HE, Reed DJ. (1981). Urinary metabolites of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea and 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Drug Metab Dispos 9:135–41
   PubMedGoogle Scholar
• Kux P. (1956). The effects of miracil D in bronchial asthma. Die Medizin 6:230
   Google Scholar
• Lang K, Siebert G, Lonnecke W. (1950). Biochemical effects of miracil D. Klin Wochenschr 28:104–5
   Google Scholar
• Latner AL, Coxon RV, King EJ. (1947). Measurement of the concentrations of miracil in biological fluids. Trans R Soc Trop Med Hyg 41:133–40
   PubMedGoogle Scholar
• Matherly LH, Voss MK, Anderson LA, et al. (1985). Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitro. Cancer Res 45:1073–8
   PubMedGoogle Scholar
• Mauss H. (1948). Basically substituted xanthone and thiaxanthon derivatives; Miracil, a new chemotherapeutic agent. Chem Ber 81:19–31
   Google Scholar
• Milligan AJ, Katz HR, Leeper DB. (1978). Effect of lucanthone hydrochloride on the radiation response of intestine and bone marrow of the Chinese hamster. J Natl Cancer Inst 60:1023–8
   PubMed Web of Science ®Google Scholar
• Morris JE, Price JM. (1963). Origin of the taurine moiety of quinaldylglycyltaurine. J Biol Chem 238:3963–5
   PubMedGoogle Scholar
• Naidu MD, Agarwali R, Pena LA, et al. (2011). Lucanthone and its derivative hycanthone inhibit apurinic endonuclease-1 (APE1) by direct protein binding. PLoS One 6:e23679 (1–16)
   Google Scholar
• Nair MG, Baugh CM. (1973). Synthesis and biological evaluation of poly-gamma-glutamyl derivatives of methotrexate. Biochemistry 12:3923–7
   PubMedGoogle Scholar
• Newsome J, Robinson DLH. (1960). Preliminary observations on metabolites of lucanthone. Trans R Soc Trop Med Hyg 54:582–4
   PubMedGoogle Scholar
• Nobler MP, Scher AJ. (1978). Lucanthone as a radiosensitizing agent in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 4:1039–44
   PubMed Web of Science ®Google Scholar
• Pelecanou M, Catsoulacos P. (1989). On the action of lucanthone and its analog hycanthone. Epith Klin Farmakol Farmakok, Int Ed 3:13–21
   Google Scholar
• Pica-Mattoccia L, Cioli D. (1986). Lack of correlation between schistosomicidal and anticholinergic properties of hycanthone and related drugs. J Parasitol 72:531–9
   PubMedGoogle Scholar
• Pinto JD, Camien MN, Dunn MS. (1965). Metabolic fate of p,p′-DDT (1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane) in rats. J Biol Chem 240:2148–54
   PubMed Web of Science ®Google Scholar
• Rosi DG, Lewis TR, Lorenz R, et al. (1967a). Preparation and schistosomicidal activity of some 4-hydroxymethyl-3-chloroanilines. J Med Chem 10:877–80
   PubMedGoogle Scholar
• Rosi D, Peruzzotti G, Dennis EW, et al. (1965). A new active metabolite of miracil D. Nature 208:1005
   PubMed Web of Science ®Google Scholar
• Rosi D, Peruzzotti G, Dennis EW, et al. (1967b). Hycanthone, a new active metabolite of lucanthone. J Med Chem 10:867–76
   PubMed Web of Science ®Google Scholar
• Sallam L A, El-Refai A, Shoeb HA. (1971). Microbiological transformations of lucanthone. Indian J Exp Biol 9:276–7
   PubMedGoogle Scholar
• Shin YS, Buehring KU, Stokstad ELR. (1974). The metabolism of methotrexate in Lactobacillus casei and rat liver and the influence of methotrexate on the metabolism of folic acid. J Biol Chem 249:5772–7
   PubMedGoogle Scholar
• Steventon GB, Hutt AJ. (2002). The amino acid conjugations. In: Ioannides C, ed. Enzyme systems that metabolise drugs and other xenobiotics. Chichester: John Wiley & Sons Ltd., 501–20
   Google Scholar
• Strufe R. (1963). Stoffwechsel-Untersuchungen mit Miracil D. Med Chem Abhandl Med-Chem (Forschungsstaeten Fabwerke Hoechst AG) 7:337–66
   Google Scholar
• Tomosky-Sykes TK, Bueding E. (1977). Effects of hycanthone on neuromuscular systems of Schistoma mansoni. J Parasitol 63:259–66
   PubMedGoogle Scholar
• Turner S, Bases R, Pearlman A, et al. (1975). The adjuvant effect of lucanthone (miracil D) on clinical radiation therapy. Radiology 114: 729–31
   PubMed Web of Science ®Google Scholar
• Walker AJ. (1948). Aspects and prospects of schistosomiasis control on the Kenyan coast. E Afr Med J 25:362–6
   Google Scholar
• Waring RH, Mitchell SC. (1985). The metabolism of phenothiazine in the neonatal calf: Identification of drug-polypeptide conjugates from urine. Xenobiotica 15:459–68
   PubMed Web of Science ®Google Scholar
• Watson JM, Abdel Azim M, Halawani A. (1948). Investigations on the antibilharzial action of Miracil D. Trans R Soc Trop Med Hyg 42:37–54
   PubMed Web of Science ®Google Scholar
• Whitehead VM, Perrault MM, Steiener S. (1975). Tissue-specific synthesis of methotrexate polyglutamates in the rat. Cancer Res 35:2985–90
   PubMed Web of Science ®Google Scholar
• Wittke S, Fliser D, Haubitz M, et al. (2003). Determination of peptides and proteins in human urine with capillary electrophoresis – mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatog A 1013:173–81
   PubMed Web of Science ®Google Scholar
• Zaman S. (2000). Enzymes involved in the bioreduction of lucanthone sulfoxide. M.S. thesis. Department of Pharmaceutical Sciences and Allied Health Professionals, St. John’s University, Jamaica, New York, 11439. pp. 154
   Google Scholar
• Zeden HH, El-Tayeb OM, Walash MN. (1983). Microbial transformation of lucanthone by growing cultures, washed mycelia and non-germanating spores of fungi from the Aspergillus group. J Gen Microbiol 129:1035–44
   PubMedGoogle Scholar
• Zilversmit R. (1971). Thioxanthones. II. Studies on the hydrogen bonding capacity of lucanthone. Mol Pharmacol 7:674–82
   PubMedGoogle Scholar